Registration is now open for the UCSF Annual Tobacco and Other Industry Documents Workshop. The workshop, which is a joint project of UCSF’s Center for Tobacco Control Research and Education and the UCSF Library will again be held virtually on October 8th from 9am-12:15pm Pacific Time. Participants will gain comprehensive knowledge of UCSF’s Industry DocumentsContinue reading “Register for free UCSF indusry documents workshop Oct 8”
Category Archives: dual use
Wide-ranging podcast with ProfGlantz
Douglas County Oregon Public Health recently released an hour long interview Mitchell Kilkenny conducted with me covering everything from how I got involved with tobacco control through secondhand smoke’s effects to our recent research showing that for for many diseases e-cigarettes have indistinguishable risks to smoking, why the tobacco free generation” is a bad idea,Continue reading “Wide-ranging podcast with ProfGlantz”
FDA should not renew permission for PMI Swedish Match snus to make modified risk claims
My UCSF colleagues and I submitted this public comment to FDA last week opposing renewal of its marketing order allowing PMI’s Swedish Match Snus to make modified risk claims. (This is an updated version of the comment we submitted to TPSAC on June 10, 2024. I was backpacking when the comment was actually submitted, henceContinue reading “FDA should not renew permission for PMI Swedish Match snus to make modified risk claims”
Criticism of our meta-analysis of e-cigarettes and disease and our response is published
NEJM Evidence has published two letters to the editor that raised questions about our meta-analysis, Population-Based Disease Odds for E-Cigarettes and Dual Use versus Cigarettes that concluded that for cardiovascular disease, stroke and metabolic disorder e-cigarette risks are similar to cigarettes and for respiratory and oral disease, while lower risk than cigarettes, the risks areContinue reading “Criticism of our meta-analysis of e-cigarettes and disease and our response is published”
DOJ and DEA should reclassify marijuana from Schedule I to Schedule III to identify regulatory approaches from tobacco to apply to cannabis
My UCSF colleagues and I submitted this comment to DOJ supporting reschduling marijuana from Schedule I to Schedule III ( PDF). The regulations.gov tracking number is lyx-h4jq-93z8. The Department of Justice and Drug Enforcement Agency should reclassify marijuana from Schedule I to Schedule III to allow consideration of the health, safety, and abuse liability impactsContinue reading “DOJ and DEA should reclassify marijuana from Schedule I to Schedule III to identify regulatory approaches from tobacco to apply to cannabis”
New meta-analysis of e-cigs and cardiovascular disease shows increased risks
Chen Chen and colleagues recently published Assessing the association between e-cigarette use and cardiovascular disease: A meta-analysis of exclusive and dual use with combustible cigarettes that found significantly elevated cardiovascular disease risk in dual users (people who use both e-cigarettes and cigarettes) and former smokers who had switched to e-cigarettes compared to people who hadContinue reading “New meta-analysis of e-cigs and cardiovascular disease shows increased risks”
FDA should consider the significant public health issues, especially for youth, created by PMI co-marketing of its Swedish Match General Snus and ZYN oral nicotine products and not reauthorize modified risk claims for General Snus
My colleagues at UCSF and I submitted this comment to the FDA Tobacco Products Scientific Advisory Committee opposing extension of PMI’s current authorization to make modified risk claims because its co-marketing with its ZYN nicotine pouch is fundamentally misleading. TPSAC is holding a meeting to discuss the modified risk request on June 26, 2024. AContinue reading “FDA should consider the significant public health issues, especially for youth, created by PMI co-marketing of its Swedish Match General Snus and ZYN oral nicotine products and not reauthorize modified risk claims for General Snus”
Implications of new RCT showing similar effects on quitting for nicotine e-cigs vs varenicline
Almost all the randomized controlled trials of e-cigarettes as clinical interventions for smoking cessation have compared e-cigarettes to nicotine replacement therapy. Varenicline, which is a prescription medication that works by blocking nicotine receptors rather than replacing the nicotine that cigarettes provide, is more effective than NRT. Anna Tsiku and colleagues new paper “Electronic Cigarettes vsContinue reading “Implications of new RCT showing similar effects on quitting for nicotine e-cigs vs varenicline”
English vaping reverses nicotine decline
In England, the country that has most aggressively embraced e-cigarettes, authorities have long minimized the effects of e-cigarettes on youth and argued that they were improving public health by attracting smokers or displacing cigarette use. Now Harry Tattan-Birch and colleagues have blown those arguments away. Their May 23, 2024 paper Trends in vaping and smokingContinue reading “English vaping reverses nicotine decline”
FDA did the right thing when it withdrew its 2022 Juul marketing denial order; it should finish the job quickly by prohibiting Juul on solid grounds
On June 6, 2024, two years after the FDA issued, then suspended its Marketing Denial Order for Juul e-cigarettes based on narrow toxicology issues, FDA formally withdrew the MDO. This does not mean that the FDA has authorized Juul for sale in the US, it just lets FDA start over in its assessment of whetherContinue reading “FDA did the right thing when it withdrew its 2022 Juul marketing denial order; it should finish the job quickly by prohibiting Juul on solid grounds”
Stanton Glantz blog 